European Union - English - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - multiple myeloma - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Canada - English - Health Canada

janssen inc - ciltacabtagene autoleucel - suspension - 100000000cells - ciltacabtagene autoleucel 100000000cells